Post Myocardial Infarction Or Peripheral Arterial Disease With Vorapaxar Therapeutics
1. Zontivity patent expiration
Treatment: Reduction of thrombotic cardiovascular events; Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7235567 | KEY THERAP | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
Jun, 2021
(4 years ago) | |
| US7304078 | KEY THERAP | Thrombin receptor antagonists |
Dec, 2027
(1 year, 11 months from now) | |
| US7713999 | KEY THERAP | Thrombin receptor antagonists |
May, 2024
(1 year, 7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Dosage: TABLET
More Information on Dosage
ZONTIVITY family patents
